Two U.S. senators sent a letter to GIlead Sciences, Inc. asking the biopharmaceutical company to explain why the cost of its new, highly promising hepatitis C drug, Sovaldi, is $84,000. The senators worry it will hurt Medicare, Medicaid, and other government-funded programs.